FDA Approves Eton's DESMODA, A New Era for Diabetes Insipidus Care

DEER PARK, IL – February 25, 2026 – The U.S. Food and Drug Administration (FDA) has granted approval to Eton Pharmaceuticals for DESMODA™ (desmopressin acetate) Oral Solution, a landmark decision that introduces the first and only oral liquid version of desmopressin for patients of all ages battling central diabetes insipidus. The approval marks a significant advancement in treating the rare endocrine disorder, promising to eliminate imprecise and often stressful dosing methods that have challenged patients and clinicians for decades.

Eton Pharmaceuticals, an innovative company focused on rare diseases, announced the approval today, with a commercial launch planned for March 9th. The new therapy is designed to provide precise, individualized dosing for a condition where maintaining the body's delicate water balance is critical for survival and well-being.

Addressing a Critical Unmet Need

Central diabetes insipidus, also known as arginine vasopressin deficiency (AVP-D), is a rare condition caused by the brain's failure to produce adequate amounts of the hormone vasopressin. This deficiency leads to extreme thirst and the excretion of large volumes of dilute urine, a state that can quickly lead to life-threatening dehydration. For the more than 13,000 patients in the U.S., including an estimated 3,000 to 4,000 children, daily treatment with the synthetic hormone desmopressin is the standard of care.

However, treatment has long been complicated by the limitations of existing formulations. Oral tablets, the most common option, often require splitting or crushing to achieve the correct dosage, especially for pediatric patients or those needing fine adjustments. This manual manipulation can lead to inconsistent dosing, risking either ineffective treatment or dangerous side effects. Other options, like nasal sprays, can have variable absorption, while injections are generally unsuitable for long-term home use.

DESMODA, a ready-to-use oral solution, directly confronts these challenges. By providing a liquid formulation, it allows clinicians and caregivers to measure the exact dose required, ensuring consistency and accuracy with every administration. This is particularly transformative for the parents of young children with the condition.

“For families living with central diabetes insipidus/AVP-D, treatment demands precision, consistency, and careful management of dosing,” said Muriël Marks, a board member of Worldwide Adrenal and Pituitary Organizations (‘WAPO’). “A liquid option like DESMODA is a meaningful improvement because it helps make sure that the dose is always right, every time. This is very important in cases where the wrong dose can have a big impact.”

The Science of Precision Dosing

The clinical imperative for a liquid formulation is rooted in the narrow therapeutic window of desmopressin. Effective management of central diabetes insipidus depends on accurately matching the dose to each patient's unique needs, which can fluctuate. Over-treatment can lead to excessive water retention and a dangerous drop in blood sodium levels known as hyponatremia. Severe hyponatremia can cause headaches, nausea, seizures, coma, and even death. Under-treatment, conversely, leaves the patient vulnerable to severe dehydration and its associated complications.

“Central diabetes insipidus requires careful, individualized management, where dosing precision and flexibility truly matter,” noted Dr. Lewis Blevins, Director of the California Center for Pituitary Disorders at the University of California, San Francisco. “Having a liquid formulation of desmopressin has the potential to meaningfully support how we initiate and manage therapy. It’s encouraging to see innovation that directly addresses real-world challenges faced by clinicians and families and gives greater confidence when tailoring treatment across age groups.”

By enabling incremental dose adjustments, DESMODA is expected to help clinicians better navigate the fine line of water balance, reducing the risk of complications. The product's prescribing information includes important warnings about the risk of hyponatremia, advising fluid restriction and careful monitoring, particularly in pediatric and geriatric patients who are at higher risk.

A Strategic Launch for Eton's Portfolio

The approval of DESMODA is a cornerstone event for Eton Pharmaceuticals, which has strategically built a portfolio of treatments for rare diseases. CEO Sean Brynjelsen described the product as “one of the most important product launches in Eton’s history,” highlighting its alignment with the company's focus on rare endocrine conditions.

The company projects that DESMODA could generate peak annual sales between $30 and $50 million. This forecast is supported by its status as a first-in-class formulation and robust intellectual property protection, with patents extending through 2044. This long runway of market exclusivity provides a significant competitive advantage and positions DESMODA as a potential long-term growth contributor for the company.

Eton plans to leverage its existing commercial infrastructure, deploying its specialized pediatric endocrinology sales force that already promotes other rare disease products like ALKINDI SPRINKLE® and INCRELEX®. This synergy allows for an efficient and targeted marketing effort aimed at the clinicians who are most likely to treat central diabetes insipidus.

Ensuring Patient Access and Commercial Rollout

Recognizing that access is a critical component of a successful launch, especially in the rare disease space, Eton has developed a comprehensive commercialization strategy. DESMODA will be available exclusively through Anovo, a specialty pharmacy that focuses on serving patients with rare and chronic conditions.

This exclusive partnership is designed to provide high-touch support for patients and their families. Specialty pharmacies like Anovo are equipped to handle complex insurance verifications, provide patient education, and manage adherence programs. To further reduce barriers, Eton is launching the Eton Cares Program, a patient support service administered in partnership with Anovo. The program will offer a suite of services including prescription fulfillment, benefits investigation, educational support, and financial assistance.

Crucially, the Eton Cares Program will feature a co-pay assistance component, enabling qualifying patients to access DESMODA with a $0 co-pay. This type of support is vital for ensuring that patients can obtain and afford innovative therapies without delay, regardless of their financial situation or insurance coverage. By integrating a specialized pharmacy and a robust patient assistance program, Eton aims to ensure a smooth and supportive experience for every patient starting on the new therapy.